Predictors of adverse outcome in cancer patients with candidemia

American Journal of Medicine

Volumn 104, Issue 3, 1998, Pages 238-245

  Anaissie, Elias J ^a,d   Rex, John H ^b   Uzun, Ömrün ^c   Vartivarian, Shahe ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b C AND EN   (United States)

^c HACETTEPE UNIVERSITY   (Turkey)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ADULT; AGED; ARTICLE; BLOOD CULTURE; CANDIDIASIS; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; CANDIDIASIS; FEMALE; FUNGEMIA; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 19244378525     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00030-8     Document Type: Article

References (33)

1. 1. Wey SB, Mori M, Pfaller MA, et al. Hospital acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med. 1988;148:2642-2645.
2. 2. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med. 1989;149:2349-2353.
3. 3. Pittet D, Tarara D, Wenzel RP. Noscomial bloodstream infection in critcally ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271:1598-1601.
4. 4. Bodey GP, Anaissie EJ, Edwards JE. Definitions of Candida infections. In: Bodey GP, ed. Candidiasis: Pathogenesis, Diagnosis, and Treatment. New York: Raven Press; 1993:407-408.
5. 5. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis. 1985;7:646-655.
6. 6. Iwama A, Yoshida M, Miwa A, et al. Improved survival from fungaemia in patients with haematological malignancies: analysis of risk factors for death and usefulness of early antifungal therapy. Eur J Haematol. 1993;51:156-160.
7. 7. Klein JJ, Watanakunakorn C. Hospital-acquired fungemia: its natural course and clinical significance. Am J Med. 1979;67:51-58.
8. 8. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989;11:379-390.
9. 9. Lecciones JA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis. 1992;14:875-883.
10. 10. Maksymiuk AW, Thonprasert S, Hopfer R, et al. Systemic candidiasis in cancer patients. Am J Med. 1984;77(4D):20-27.
11. 11. Martino P, Girmenia C, Micozzi A, et al. Fungemia in patients with leukemia. Am J Med Sci. 1993;306:225-232.
12. 12. Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med. 1995;155:2429-2435.
13. 13. Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease: a study of 364 cases. Am J Med. 1977;62:731-742.
14. 14. Whimbey E, Kiehn TE, Brannon P, et al. Bacteremia and fungemia in patients with neoplastic disease. Am J Med. 1987;82:723-730.
15. 15. Young RC, Bennett JE, Geelhoed GW, Levine AS. Fungemia with compromised host resistance: a study of 70 cases. Ann Intern Med. 1974;80:605-612.
16. 16. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992;15:414-421.
17. 17. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. NEJM. 1994;331:1325-1330.
18. 18. Phillips P, Shafran S, Garber G, et al. Fluconazole (FLU) versus amphotericin B (AMB) for candidemia in non-neutropenic patients: a multicenter randomized trial. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstract No. LM20.
19. 19. Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchanges and the duration of candidemia. Clin Infect Dis. 1995;21: 994-996.
20. 20. Le Gall J-R, Loirat P, Alperovitch A, et al. A simplified acute physiology score for ICU patients. Crit Care Med. 1984;11:975-977.
21. 21. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991;100:1619-1636.
22. 22. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1993;115: 457-469.
23. 23. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996;23:964-972.
24. 24. Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying intravenous-catheter related infection. NEJM. 1977;23:1305-1309.
25. 25. Berenguer J, Buck M, Witebsky F, et al. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis. 1993;17:103-109.
26. 26. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med. 1996;101:170-176.
27. 27. Bodey GP. Fungal infections complicating acute leukemia. J Chron Dis. 1966;19:667-687.
28. 28. Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997;24:1122-1128.
29. 29. Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host: changing patterns, antigenemia, high mortality. Am J Med. 1981;71:363-370.
30. 30. Lowder JN, Lazarus HM, Herzig RH. Bacteremias and fungemias in oncologic patients with central venous catheters. Changing spectrum of infection. Arch Intern Med. 1982;142:1456-1459.
31. 31. Karabinis A, Hill C, Leclerq B, et al. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol. 1988;26:429-432.
32. 32. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis. 1995;21:361-369.
33. 33. DeGregorio MW, Lee WMF, Ries CA. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer. 1982;50:2780-2784.